AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Wednesday, November 8th.
According to Zacks, “AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry. Nevertheless, the company is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share.”
Several other equities analysts also recently commented on AMAG. Cantor Fitzgerald reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Monday, July 24th. ValuEngine upgraded shares of AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 25th. Cowen Inc restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Thursday, August 10th. BidaskClub downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, Deutsche Bank AG restated a “hold” rating and issued a $24.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, August 31st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and three have assigned a buy rating to the stock. AMAG Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $24.00.
Hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue lifted its holdings in shares of AMAG Pharmaceuticals by 81.3% in the second quarter. State of Alaska Department of Revenue now owns 6,871 shares of the specialty pharmaceutical company’s stock worth $126,000 after acquiring an additional 3,081 shares during the last quarter. Municipal Employees Retirement System of Michigan lifted its position in AMAG Pharmaceuticals by 6.6% in the second quarter. Municipal Employees Retirement System of Michigan now owns 8,280 shares of the specialty pharmaceutical company’s stock valued at $152,000 after purchasing an additional 510 shares during the last quarter. Hartford Investment Management Co. bought a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $186,000. Cubist Systematic Strategies LLC bought a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $197,000. Finally, 361 Capital LLC bought a new stake in AMAG Pharmaceuticals in the third quarter valued at approximately $197,000.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.